Get the latest news, insights, and market updates on CNSP (CNS Pharmaceuticals, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year
“Oncology drug development can be complex and challenging, but the GBM patients who live with this devastating condition in the shadow of a significant unmet medical need keep us motivated and determined to succeed. Although our recently announced findings from the primary analysis of our Berubicin study did not meet its primary target, it provided valuable insight and proof in a large dataset that Berubicin is safe, well-tolerated and has activity against GBM, attributes that few compounds have Apr 2, 2025 - $CNSP
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in glioblastoma multiforme (GBM) for ... Apr 1, 2025 - $CNSP
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple